These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15210143)

  • 1. Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity.
    Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M; Caruso PL; Galbiati E; Lipreri M; Rivara S; Lodola A; Mor M
    Bioorg Med Chem; 2004 Jul; 12(14):3763-82. PubMed ID: 15210143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
    Jain N; Xu J; Kanojia RM; Du F; Jian-Zhong G; Pacia E; Lai MT; Musto A; Allan G; Reuman M; Li X; Hahn D; Cousineau M; Peng S; Ritchie D; Russell R; Lundeen S; Sui Z
    J Med Chem; 2009 Dec; 52(23):7544-69. PubMed ID: 19366247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification.
    Richardson TI; Dodge JA; Durst GL; Pfeifer LA; Shah J; Wang Y; Durbin JD; Krishnan V; Norman BH
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4824-8. PubMed ID: 17614275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.
    Richardson TI; Norman BH; Lugar CW; Jones SA; Wang Y; Durbin JD; Krishnan V; Dodge JA
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3570-4. PubMed ID: 17485205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
    Yang C; Xu G; Li J; Wu X; Liu B; Yan X; Wang M; Xie Y
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1505-7. PubMed ID: 15713417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor ligands. Part 6: Synthesis and binding affinity of dihydrobenzodithiins.
    Tan Q; Birzin ET; Chan W; Yang YT; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3753-5. PubMed ID: 15203156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer.
    Kumar S; Deshpande S; Chandra V; Kitchlu S; Dwivedi A; Nayak VL; Konwar R; Prabhakar YS; Sahu DP
    Bioorg Med Chem; 2009 Oct; 17(19):6832-40. PubMed ID: 19740667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
    Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective estrogen receptor modulator for the treatment of hot flushes.
    Wallace OB; Lauwers KS; Dodge JA; May SA; Calvin JR; Hinklin R; Bryant HU; Shetler PK; Adrian MD; Geiser AG; Sato M; Burris TP
    J Med Chem; 2006 Feb; 49(3):843-6. PubMed ID: 16451049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
    J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
    Mukherjee S; Saha A; Roy K
    Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
    Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
    J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular simulation of interaction between estrogen receptor and selective estrogen receptor modulators.
    Guo ZR; Yi X; Xu ZB
    Acta Pharmacol Sin; 2002 Mar; 23(3):208-12. PubMed ID: 11918843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies.
    Richardson TI; Dodge JA; Wang Y; Durbin JD; Krishnan V; Norman BH
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5563-6. PubMed ID: 17804226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring.
    Norman BH; Richardson TI; Dodge JA; Pfeifer LA; Durst GL; Wang Y; Durbin JD; Krishnan V; Dinn SR; Liu S; Reilly JE; Ryter KT
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5082-5. PubMed ID: 17662603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs.
    Tan Q; Blizzard TA; Morgan JD; Birzin ET; Chan W; Yang YT; Pai LY; Hayes EC; DaSilva CA; Warrier S; Yudkovitz J; Wilkinson HA; Sharma N; Fitzgerald PM; Li S; Colwell L; Fisher JE; Adamski S; Reszka AA; Kimmel D; DiNinno F; Rohrer SP; Freedman LP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1675-81. PubMed ID: 15745820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzothiophene and naphthalene derived constrained SERMs.
    Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androstene-3,5-dienes as ER-beta selective SERMs.
    Blizzard TA; Gude C; Morgan JD; Chan W; Birzin ET; Mojena M; Tudela C; Chen F; Knecht K; Su Q; Kraker B; Mosley RT; Holmes MA; Rohrer SP; Hammond ML
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6295-8. PubMed ID: 17890084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of dehydroaltenusin derivatives as selective DNA polymerase alpha inhibitors.
    Kuramochi K; Fukudome K; Kuriyama I; Takeuchi T; Sato Y; Kamisuki S; Tsubaki K; Sugawara F; Yoshida H; Mizushina Y
    Bioorg Med Chem; 2009 Oct; 17(20):7227-38. PubMed ID: 19767211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.